Indaptus Therapeutics Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Junyi Dai

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyseartikel • Mar 27

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyseartikel • Aug 15

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Aug 08

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Indaptus Therapeutics press release (NASDAQ:INDP): Q2 GAAP EPS of -$0.46 beats by $0.45. As of June 30, 2022, the Company had cash, cash equivalents and short-term investments of approximately $33.0 million. As of December 31, 2021, the Company had cash and cash equivalents of approximately $39.1 million.

Seeking Alpha • Sep 29

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

Indaptus Therapeutics is advancing the Decoy bacteria triggered immune response technology for cancer and viral indications. The company was formed from the reverse merger of Intec Pharma and Decoy Biosystems. Shares of the company commenced trading on Nasdaq on August 4, 2021.

CEO

Junyi Dai (38 yo)

less than a year

Tenure

Mr. Junyi Dai is CEO & Chairman of Indaptus Therapeutics, Inc. from March 18, 2026. He had been an Independent Director of Mega Matrix Corp. from May 10, 2024 until December 30, 2025. He served as Managing...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Newman	Founder	4.8yrs	US$1.69m	4.51% $ 6.2m
Walt Linscott	Chief Operating Officer	3.2yrs	US$1.95m	2.43% $ 3.4m
Junyi Dai	CEO & Chairman	less than a year	geen gegevens	geen gegevens
Yu Ding	Chief Financial Officer	less than a year	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van INDP wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Newman	Founder	4.8yrs	US$1.69m	4.51% $ 6.2m
Junyi Dai	CEO & Chairman	less than a year	geen gegevens	geen gegevens
David Natan	Independent Director	less than a year	geen gegevens	geen gegevens
Jerome Jabbour	Independent Director	less than a year	geen gegevens	geen gegevens
Avraham Ben-Tzvi	Director	less than a year	geen gegevens	1.12% $ 1.5m
David Lazar	Director	less than a year	geen gegevens	geen gegevens
Tim Ruan	Independent Director	less than a year	geen gegevens	geen gegevens
Qinglai Lu	Independent Director	less than a year	geen gegevens	geen gegevens
Yi Zhang	Independent Director	less than a year	geen gegevens	geen gegevens

0.3yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INDP wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.3 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/24 09:27
Aandelenkoers aan het einde van de dag	2026/05/22 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Indaptus Therapeutics, Inc. wordt gevolgd door 1 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Jason McCarthy	Maxim Group

Indaptus Therapeutics Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Indaptus Therapeutics, Inc. Appoints David Natan as A Class II Director

Less than half of directors are independent

Indaptus Therapeutics, Inc. Announces Resignations of Board Members Michael Newman, Mark Gilbert, and Anthony Maddaluna

Indaptus Therapeutics, Inc., Annual General Meeting, Jun 10, 2025

Insufficient new directors

Recent updates

New major risk - Revenue and earnings growth

New major risk - Financial position

High number of new directors

Indaptus Therapeutics, Inc. Appoints David Natan as A Class II Director

Less than half of directors are independent

Indaptus Therapeutics, Inc. Announces Resignations of Board Members Michael Newman, Mark Gilbert, and Anthony Maddaluna

Forecast to breakeven in 2028

Indaptus Therapeutics, Inc. announced that it expects to receive $6 million in funding

New major risk - Financial position

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.375 million.

New major risk - Financial position

Indaptus Therapeutics, Inc. announced that it has received $3.4 million in funding

Indaptus Therapeutics, Inc. announced that it has received $2.3 million in funding

Indaptus Therapeutics Doses First Patient in Phase 1B/2 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor Tislelizumab

New minor risk - Share price stability

New major risk - Financial position

Indaptus Therapeutics, Inc., Annual General Meeting, Jun 10, 2025

New major risk - Market cap size

Indaptus Therapeutics, Inc. Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening Its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics, Inc. announced that it expects to receive $20 million in funding from Yorkville Advisors Global LP

Indaptus Therapeutics, Inc. Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirements

Indaptus Therapeutics, Inc. announced that it has received $2.246493 million in funding

New major risk - Shareholder dilution

Indaptus Therapeutics, Inc. announced that it expects to receive $2.246493 million in funding

New major risk - Market cap size

Insufficient new directors

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.134995 million.

New major risk - Financial position

Indaptus Therapeutics, Inc. Presents Clinical Data on Decoy20 at SITC 2024 Annual Meeting

Indaptus Therapeutics, Inc. Provides Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

New minor risk - Shareholder dilution

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000003 million.

Indaptus Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.3 million.

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

New major risk - Financial position

New minor risk - Share price stability

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial

Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20

Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023

Price target increased by 15% to US$15.00

Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Price target decreased to US$11.00

High number of new and inexperienced directors

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Indaptus Therapeutics, Inc., Annual General Meeting, Sep 29, 2022

CEO & Director recently bought US$52k worth of stock

Indaptus Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

High number of new and inexperienced directors

High number of new and inexperienced directors

CEO & Director recently bought US$65k worth of stock

Insider recently bought US$691k worth of stock

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

CEO & Director recently bought US$84k worth of stock

CEO

Leiderschapsteam

Bestuursleden

Bedrijfsanalyse en status van financiële gegevens

Gegevensbronnen

Analysemodel en Snowflake